Clinical Trial Update: Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tremelimumab and durvalumab with or without radiation therapy in relapsed small cell lung cancer has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Emory University | Conditions: Recurrent Small Cell Lung Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2021-06-22